Matteo Rocco Pastore

Biography

Dr Matteo Rocco Pastore is responsible for the Department of Simple General Medicine dealing with Diabetes, Endocrinology and Metabolic Diseases in the Operational Division of General Medicine for Diabetes and Endocrine Metabolism at the IRCCS Ospedale San Raffaele under the supervision of Professor Emanuele Bosi.

After graduating from the University of Milan in 1986 with a degree in Medicine and Surgery, he specialized in Diabetology in 1989 and Endocrinology in 2004, respectively, at the same university and the Vita Salute San Raffaele University.

With regard to clinical activities, Dr. Pastore works as a therapist in the Department of General Medicine with diabetic and endocrine-metabolic direction and provides specialist consultations in various departments of the hospital. He also carries out outpatient clinical activities in the field of diabetology, paying special attention to the treatment of type 1 diabetes.

He conducts research activities in the field of prediction and prevention of type 1 diabetes and its complications as co-leader of the international research protocol TrialNet.

He is the author and co-author of more than 50 publications in industry scientific journals and book chapters. His Hirsch Index is 11 (WoS). Constantly takes part in national and international industry congresses.

Education

University of Milan
Degree of Doctor of Medicine and Surgery — 1986

University of Milan
Specialization in Diabetology — 1989

Vita Salute San Raffaele University
Specialization in Endocrinology — 2004

Do you need an appointment?

Contact us and we will take care of you.

Publications

Latest publications

Endothelial progenitor cells carrying monocyte markers are selectively abnormal in type 1 diabetic patients with early retinopathy
https://www.ncbi.nlm.nih.gov/pubmed/22338095
Gianpaolo Zerbini, Anna Maestroni, Alessio Palini, Gemma Tremolada, Rosangela Lattanzio, Silvia Maestroni, Matteo Rocco Pastore, Antonio Secchi, Riccardo Bonfanti, Chiara Gerhardinger, Mara Lorenzi
Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk
Diabetologia. May; 49(5):881-90, 2006
P. J. Bingley . E. A. M. Gale . The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group
Read more
Increased clonogenic potential of circulating endothelial progenitor cells in patients with type 1 diabetes and proliferative retinopathy
Diabetologia. May;49(5):1109-11, 2006.
Asnaghi V, Lattanzio R, Mazzolari G, Pastore MR, Ramoni A, Maestroni A, Ruggeri D, Luzi L, Brancato R, Zerbini G
Read more
Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk
Diabetologia, May;49(5):881-90, 2006.
P. J. Bingley . E. A. M. Gale . The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group
Read more
Lactulose and mannitol intestinal permeability detected by capillary electrophoresis
J Chromatogr B Analyt Technol Biomed Life Sci. Apr 13;834(1-2):183-7, 2006
Paroni R, Fermo I, Molteni L, Folini L, Pastore MR, Mosca A, Bosi E.
Read more
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes
Lancet 363(9413):925-34, 2004
Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group.
Read more
Six months of gluten-free diet do not change islet autoantibodies, but improve insulin secretion in subjects at high risk for type 1 diabetes
J Clin Endocrinol Metab 88: 162-165, 2003.
Pastore MR, Bazzigaluppi E, Belloni C, Arcovio C, Bonifacio E, Bosi E.
Read more
Update on Worldwide Efforts to Prevent Type 1 Diabetes
Ann N Y Acad Sci 2008;1150:190-196. PMID 19120293, NIHMS225042
Skyler JS and the Type 1 Diabetes TrialNet Study Group
Read more
Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes
Diabetes Care 2008;31:1966-1971. PMID 18628574, PMC2251636
Greenbaum CJ, Mandrup-Poulsen T, Friedenberg-McGee P, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, and The Type 1 Diabetes TrialNet Research Group and The European C-peptide Trial Study Group
Read more
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.
Pediatric Diabetes 2009;10:97-104. PMID 18823409
Mahon J, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet Natural History Committee and Type 1 Diabetes TrialNet Study Group.
Read more
The Validation of the Diabetes Prevention Trial-Type 1 Risk Score and the detection of Pre-Diabetes in the TrialNet Natural History Study
Diabetes Care 2011;34:1785-1787. PMID: 21680724,PMC3142063.
Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, the TrialNet and Diabetes Prevention Trial – Type 1 Study Groups
Read more
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies
Diabetes Care. 2012 Jun;35(6):1213-8. doi: 10.2337/dc11- 2081. Epub 2012 Mar 23
Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; Type 1 Diabetes TrialNet Study Group.
Read more
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes
Diabetes Care. 2012 Jul;35(7):1552-5. doi: 10.2337/dc12-0011. Epub 2012 Apr 30
Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.
Read more
Performance of HbA1c as an early diagnostic indicator of type 1 diabetes in children and youth
Diabetes Care. 2012 Sep;35(9):1821-5. Epub 2012 Jun 14
Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M, Rewers MJ, Schatz DA, Krischer JP; TEDDY, TRIGR, Diabetes Prevention Trial–Type 1, and Type 1 Diabetes TrialNet Natural History Study Groups
Read more
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients
Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1
Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group
Read more
Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: A Feasibility Study.
Diabetes Technol Ther. 2015 Dec;17(12):867-71. doi: 10.1089/dia.2015.0133. Epub 2015 Sep 16
Bingley PJ, Rafkin LE, Matheson D, Steck AK, Yu L, Henderson C, Beam CA, Boulware DC; TrialNet Study Group.
Read more
The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants
Diabetologia. 2016 Jun;59(6):1186-95. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19
Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C; Type 1 Diabetes TrialNet Study Group
Read more

Do you need an appointment?

Contact us and we will take care of you.